Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV

Clinical Infectious Diseases

Volumn 64, Issue 9, 2017, Pages 1154-1162

  Young, Jim ^a,b   Rossi, Carmine ^a   Gill, John ^c   Walmsley, Sharon ^d,e   Cooper, Curtis ^e,f   Cox, Joseph ^a   Martel Laferriere, Valerie ^g   Conway, Brian ^h   Pick, Neora ⁱ   Vachon, Marie Louise ^j   Klein, Marina B ^a,e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Southern Alberta HIV Clinic   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Canadian HIV Trials Network   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

ⁱ CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^j UNIVERSITÉ LAVAL   (Canada)

more..

Author keywords

Hepatitis C treatment; Hepatitis C virus; HIV; Reinfection; Sustained virologic response

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT;

ADULT; ARTICLE; BAYES THEOREM; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; REINFECTION; RISK ASSESSMENT; SEXUAL BEHAVIOR; SUSTAINED VIROLOGIC RESPONSE; CANADA; CHRONIC HEPATITIS C; COMPLICATION; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR;

ADULT; CANADA; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE;

EID: 85020055806     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix126     Document Type: Article

References (43)

1. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015; 10:297-302.
2. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
3. Young J, Potter M, Cox J, et al. Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study. CMAJ Open 2013; 1:E106-14.
4. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016; 62:683-94.
5. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593-601.
6. Soriano V, Núñez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIVcoinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9:505-9.
7. Martin TC, Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013; 27:2551-7.
8. Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 2013; 59:45-51.
9. Pineda JA, Núñez-Torres R, Téllez F, et al; HEPAVIR Group of the Andalusian Society of Infectious Diseases. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect 2015; 71:571-7.
10. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57 Suppl 2:S105-10.
11. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-23.
12. Marshall AD, Saeed S, Barrett L, et al; Canadian Network on Hepatitis C. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016; 4:E605-14.
13. Klein MB, Saeed S, Yang H, et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39:1162-9.
14. Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis 2009; 49:1397-401.
15. Kim AY, Onofrey S, Church DR. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 2013; 207 Suppl 1:S1-6.
16. Marcellin F, Lorente N, Demoulin B, et al; ANRS VESPA2 Study Group. Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect 2015; 91:21-3.
17. Leri F, Stewart J, Tremblay A, Bruneau J. Heroin and cocaine co-use in a group of injection drug users in Montréal. J Psychiatry Neurosci 2004; 29:40-7.
18. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000; 151:531-9.
19. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol 2006; 35:765-75.
20. Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol 2007; 36:195-202.
21. Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999; 18:2655-79.
22. Greenland S. Prior data for non-normal priors. Stat Med 2007; 26:3578-90.
23. Young J, Scherrer AU, Günthard HF, et al; Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med 2011; 12:299-307.
24. Saeed S, Strumpf EC, Walmsley SL, et al; Canadian Co-Infection Cohort Study. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world? Clin Infect Dis 2016; 62:919-26.
25. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2:S80-9.
26. Lambers FA, Prins M, Thomas X, et al; MSM Observational Study of Acute Infection With Hepatitis C Study Group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011; 25:F21-7.
27. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-17.
28. Matthews GV, Hellard M, Haber P, et al; Australian Trial in Acute Hepatitis C Study Group. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-8.
29. Boesecke C, Grint D, Soriano V, et al; EuroSIDA in EuroCoord. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Liver Int 2015; 35:2384-91.
30. Burchell AN, Gardner SL, Mazzulli T, et al. Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: results from a clinical HIV cohort. Can J Infect Dis Med Microbiol 2015; 26:17-22.
31. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010; 15:19673.
32. Wandeler G, Gsponer T, Bregenzer A, et al; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55:1408-16.
33. Weir A, McLeod A, Innes H, et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug Alcohol Depend 2016; 165:53-60.
34. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. Morb Mortal Wkly Rep 2011; 60:537-41.
35. Public Health Agency of Canada. Hepatitis C in Canada: 2005-2010 surveillance report. 2011. Available at: http://publications.gc.ca/collections/collection-2012/ aspc-phac/HP40-70-2012-eng.pdf. Accessed June 30, 2016.
36. Vickerman P, Page K, Maher L, Hickman M. Commentary on Nolan et al. (2014): opiate substitution treatment and hepatitis C virus prevention: building an evidence base? Addiction 2014; 109:2060-1.
37. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012; 345:e5945.
38. Raycraft T, Hakobyan S, Vafadary S, et al. Retrospective analysis of recurrent HCV viremia in high-risk HIV co-infected people who inject drugs (PWID). J Viral Hepat 2016; 2:2. Available at: http://hepatitis.imedpub.com/. Accessed March 7, 2017.
39. Melendez-Torres GJ, Bonell C. Systematic review of cognitive behavioural interventions for HIV risk reduction in substance-using men who have sex with men. Int J STD AIDS 2014; 25:627-35.
40. Berg R. The effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe: a systematic review. Euro Surveill 2009; 14.
41. Andraka-Christou B. A pressing need for pharmacotherapy development to treat drug addiction: an editorial from a legal perspective. Int Rev Neurobiol 2016; 126:15-38.
42. Ling W, Hillhouse MP, Saxon AJ, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction 2016; In Press.
43. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy brief. 2016. Available at: http://www.who.int/hepatitis/publications/ hep-elimination-by-2030-brief/en/. Accessed June 29, 2016.